PL1836500T3 - Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi - Google Patents
Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwiInfo
- Publication number
- PL1836500T3 PL1836500T3 PL06701801T PL06701801T PL1836500T3 PL 1836500 T3 PL1836500 T3 PL 1836500T3 PL 06701801 T PL06701801 T PL 06701801T PL 06701801 T PL06701801 T PL 06701801T PL 1836500 T3 PL1836500 T3 PL 1836500T3
- Authority
- PL
- Poland
- Prior art keywords
- vwf
- thrombocytopenia
- platelets
- von willebrand
- willebrand factor
- Prior art date
Links
- 108010047303 von Willebrand Factor Proteins 0.000 title abstract 11
- 102100036537 von Willebrand factor Human genes 0.000 title abstract 11
- 229960001134 von willebrand factor Drugs 0.000 title abstract 11
- 230000003993 interaction Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000002269 spontaneous effect Effects 0.000 title abstract 3
- 206010043554 thrombocytopenia Diseases 0.000 title abstract 3
- 208000037765 diseases and disorders Diseases 0.000 title abstract 2
- 238000003556 assay Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 239000012472 biological sample Substances 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/222—Platelet disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64441405P | 2005-01-14 | 2005-01-14 | |
| EP06701801A EP1836500B1 (en) | 2005-01-14 | 2006-01-13 | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
| PCT/EP2006/000273 WO2006074947A2 (en) | 2005-01-14 | 2006-01-13 | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1836500T3 true PL1836500T3 (pl) | 2010-12-31 |
Family
ID=36593150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06701801T PL1836500T3 (pl) | 2005-01-14 | 2006-01-13 | Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7939277B2 (pl) |
| EP (1) | EP1836500B1 (pl) |
| JP (1) | JP4829897B2 (pl) |
| AT (1) | ATE473446T1 (pl) |
| AU (1) | AU2006205900B8 (pl) |
| CA (1) | CA2593328C (pl) |
| DE (1) | DE602006015281D1 (pl) |
| DK (1) | DK1836500T3 (pl) |
| ES (1) | ES2347908T3 (pl) |
| PL (1) | PL1836500T3 (pl) |
| PT (1) | PT1836500E (pl) |
| SI (1) | SI1836500T1 (pl) |
| WO (1) | WO2006074947A2 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003251238A1 (en) * | 2002-08-07 | 2004-02-25 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
| CA2578046A1 (en) | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
| US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| PL1836500T3 (pl) | 2005-01-14 | 2010-12-31 | Ablynx Nv | Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi |
| DK2444424T3 (en) | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| WO2008049881A2 (en) * | 2006-10-25 | 2008-05-02 | Umc Utrecht Holding Bv | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| EP2615172A1 (en) | 2007-04-27 | 2013-07-17 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| EP2252303A2 (en) * | 2008-03-21 | 2010-11-24 | Ablynx NV | Von willebrand factor specific binders and methods of use therefor |
| GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| HRP20160404T8 (hr) * | 2008-12-04 | 2016-07-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Metoda za proizvodnju trombocita |
| WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| PT2473528E (pt) * | 2009-09-03 | 2015-03-04 | Ablynx NV | Formulações estáveis de polipéptidos e seus usos |
| HUE029454T2 (en) | 2009-11-13 | 2017-03-28 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| CA2961774C (en) | 2014-10-07 | 2023-05-23 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| RU2599021C1 (ru) * | 2015-07-27 | 2016-10-10 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ прогнозирования течения иммунной тромбоцитопении после спленэктомии по массе cd4+ т-лимфоцитов селезенки |
| MY204220A (en) | 2018-02-06 | 2024-08-16 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
| WO2021258160A1 (en) * | 2020-06-26 | 2021-12-30 | Monash University | Anti-vwf antibodies and uses thereof |
| WO2026017728A1 (en) | 2024-07-16 | 2026-01-22 | Synapse Research Institute | Polypeptide for treatment of microvascular thrombosis |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5238919A (en) * | 1986-05-30 | 1993-08-24 | Scipps Clinic And Research Foundation | Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor |
| US5200510A (en) | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
| US5770198A (en) * | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| GB8905400D0 (en) | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| EP1498427B1 (en) | 1992-08-21 | 2009-12-16 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| SG55079A1 (en) | 1992-12-11 | 1998-12-21 | Dow Chemical Co | Multivalent single chain antibodies |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| US5670132A (en) * | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| DK0795608T3 (da) * | 1994-11-30 | 2003-07-21 | Ajinomoto Kk | Antitrombotisk middel og monoklonale anti-von Willebrandfaktor antistoffer |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6239259B1 (en) | 1996-04-04 | 2001-05-29 | Unilever Patent Holdings B.V. | Multivalent and multispecific antigen-binding protein |
| AU740043B2 (en) | 1996-06-27 | 2001-10-25 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| AU9262598A (en) | 1997-08-18 | 1999-03-08 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| ATE535154T1 (de) * | 1998-03-12 | 2011-12-15 | Vhsquared Ltd | Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben |
| CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
| CA2344606A1 (en) | 1998-10-23 | 2000-05-04 | Huabing Yuan | Conformation-specific anti-von willebrand factor antibodies |
| EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
| WO2000043507A1 (en) | 1999-01-19 | 2000-07-27 | Unilever Plc | Method for producing antibody fragments |
| US6419934B1 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
| ES2358576T3 (es) * | 1999-07-05 | 2011-05-11 | K.U. LEUVEN RESEARCH & DEVELOPMENT | Detección de la actividad del factor de von-willebrand (vwf). |
| CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US6699473B2 (en) * | 2000-10-13 | 2004-03-02 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| GB0031448D0 (en) | 2000-12-22 | 2001-02-07 | Leuven K U Res & Dev | Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| US20050136056A1 (en) * | 2002-07-29 | 2005-06-23 | Shunsuke Kageyama | Pharmaceutical composition for the treatment of thrombocytopenia |
| AU2003251238A1 (en) * | 2002-08-07 | 2004-02-25 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| RU2357974C2 (ru) * | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| SI1639011T1 (sl) * | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| PL1836500T3 (pl) | 2005-01-14 | 2010-12-31 | Ablynx Nv | Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi |
| DK2444424T3 (en) | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| WO2008049881A2 (en) * | 2006-10-25 | 2008-05-02 | Umc Utrecht Holding Bv | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
-
2006
- 2006-01-13 PL PL06701801T patent/PL1836500T3/pl unknown
- 2006-01-13 DK DK06701801.0T patent/DK1836500T3/da active
- 2006-01-13 US US11/795,162 patent/US7939277B2/en active Active
- 2006-01-13 ES ES06701801T patent/ES2347908T3/es not_active Expired - Lifetime
- 2006-01-13 SI SI200630783T patent/SI1836500T1/sl unknown
- 2006-01-13 CA CA2593328A patent/CA2593328C/en not_active Expired - Fee Related
- 2006-01-13 PT PT06701801T patent/PT1836500E/pt unknown
- 2006-01-13 AU AU2006205900A patent/AU2006205900B8/en not_active Expired
- 2006-01-13 DE DE602006015281T patent/DE602006015281D1/de not_active Expired - Lifetime
- 2006-01-13 JP JP2007550764A patent/JP4829897B2/ja not_active Expired - Lifetime
- 2006-01-13 EP EP06701801A patent/EP1836500B1/en not_active Expired - Lifetime
- 2006-01-13 WO PCT/EP2006/000273 patent/WO2006074947A2/en not_active Ceased
- 2006-01-13 AT AT06701801T patent/ATE473446T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| DK1836500T3 (da) | 2010-11-01 |
| ES2347908T3 (es) | 2010-11-25 |
| AU2006205900B2 (en) | 2011-12-08 |
| AU2006205900A1 (en) | 2006-07-20 |
| AU2006205900B8 (en) | 2012-04-05 |
| SI1836500T1 (sl) | 2010-11-30 |
| US20080096223A1 (en) | 2008-04-24 |
| CA2593328A1 (en) | 2006-07-20 |
| WO2006074947A3 (en) | 2006-09-14 |
| AU2006205900A8 (en) | 2012-04-05 |
| JP2008527358A (ja) | 2008-07-24 |
| EP1836500B1 (en) | 2010-07-07 |
| DE602006015281D1 (de) | 2010-08-19 |
| US7939277B2 (en) | 2011-05-10 |
| PT1836500E (pt) | 2010-09-28 |
| WO2006074947A2 (en) | 2006-07-20 |
| CA2593328C (en) | 2018-02-06 |
| JP4829897B2 (ja) | 2011-12-07 |
| EP1836500A2 (en) | 2007-09-26 |
| ATE473446T1 (de) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1836500T1 (sl) | Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami | |
| DE60335022D1 (de) | Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel | |
| DE60130538D1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
| HUP0202532A2 (hu) | Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása | |
| MX2009000914A (es) | Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento. | |
| WO2008008463A3 (en) | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ | |
| ATE540319T1 (de) | Verfahren für die bestimmung von fk506 | |
| MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
| WO2005108989A3 (en) | Assay for antibodies | |
| WO2007044695A3 (en) | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF | |
| BRPI0414513A (pt) | kid3 e anticorpos de kid3 que se ligam a ele | |
| ATE504836T1 (de) | Verfahren zur identifizierung von trpv2- modulatoren | |
| EP2074427A4 (en) | Diagnostic biomolecule(s) | |
| AU2003296424A1 (en) | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | |
| DK1987057T3 (da) | Peptidaptamer til neutralisering af bindingen af platelet-antigen-specifikke antistoffer og diagnostiske og terapeutiske applikationer indeholdende den. | |
| WO2003087761A3 (en) | Molecular profiling of disease and therapeutic response using phospho-specific antibodies | |
| WO2004070025A3 (en) | Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders | |
| BRPI0414365A (pt) | composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes | |
| EP1824498A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PROLIFERATIVE CELL DISEASES | |
| Sim et al. | Unfolded von Willebrand factor binds protein S and reduces anticoagulant activity | |
| FR2930036B1 (fr) | Procede de diagnostic d'une hypertension arterielle pulmonaire. | |
| WO2007113685A3 (en) | USE OF THE α CHAIN OF BRAIN SPECTRIN AND FRAGMENTS THEREOF, FOR DIAGNOSING CEREBRAL DISEASES | |
| NO20082406L (no) | Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen | |
| AU2001250470A1 (en) | Novel antibodies specifically identifying inactive psa, and uses thereof | |
| WO2009078806A3 (en) | Skeletal muscle proteome, muscle function and physical performance |